Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 18/20 | 0.56 |
| ▸ | HTR6 | P50406 | 11/20 | 0.54 |
| ▸ | HTR2A | P28223 | 9/20 | 0.54 |
| ▸ | DRD2 | P14416 | 8/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8982971 | 0.99 | HTR7 (0.55) | HTR7HTR6HTR2ADRD2HTR1A | |
| SCHEMBL8980063 | 0.99 | HTR7 (0.55) | HTR7HTR6HTR2ADRD2HTR1A | |
| Hydrochloric Acid SCHEMBL5417558 | 0.98 | HTR7 (0.54) | HTR7HTR6HTR2ADRD2HTR1A | |
| SCHEMBL10035547 | 0.97 | HTR7 (0.55) | HTR7HTR6HTR2ADRD2HTR1A | |
| Hydrochloric Acid SCHEMBL2135275 | 0.96 | HTR7 (0.54) | HTR7HTR6HTR2ADRD2HTR1A | |
| SCHEMBL8983356 | 0.88 | DRD2 (0.53) | HTR7HTR6HTR2ADRD2HTR1A | |
| SCHEMBL10035571 | 0.85 | HTR6 (0.52) | HTR7HTR6HTR2ADRD2HTR1A | |
| Hydrochloric Acid SCHEMBL2139362 | 0.84 | DRD2 (0.53) | HTR7HTR6HTR2ADRD2HTR1A | |
| SCHEMBL8980595 | 0.78 | HTR7 (0.65) | HTR7HTR6DRD2HTR1AHRH1 | |
| SCHEMBL8980238 | 0.78 | HTR7 (0.65) | HTR7HTR6DRD2HTR1AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188115-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-05-29 | — | — | US | disclosed |
| US-8188115-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-05-29 | — | — | US | disclosed |
| US-20090163542-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| US-20090163542-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| US-7211585-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-01 | — | — | US | disclosed |
| US-7211585-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163542-A1 | 5-ht7 receptor antagonists | HTR7, HTR1A, HTR5A | HTR7 1/4885HTR6 7/4885HTR2A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.